Ascensión
López Díaz de Cerio
Profesional Investigadora
Publications (59) Ascensión López Díaz de Cerio publications
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
Blood Advances, Vol. 8, Núm. 21, pp. 5479-5492
-
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells
British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355
2023
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies
Biomedicines, Vol. 11, Núm. 2
-
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia
Frontiers in Immunology, Vol. 14
2022
-
C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d
Frontiers in Immunology, Vol. 13
-
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Science Advances, Vol. 8, Núm. 39
2021
-
Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
Therapeutic Advances in Medical Oncology, Vol. 13
-
Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma
Scientific Reports, Vol. 11, Núm. 1
-
Immunologic characterization of COVID-19 patients with hematological cancer
Haematologica
-
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Frontiers in Immunology, Vol. 12
-
Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge
Frontiers in Immunology, Vol. 12
-
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946
2020
-
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073
2019
-
Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients
Antiviral Therapy, Vol. 24, Núm. 4, pp. 313-319
-
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach
British Journal of Clinical Pharmacology, Vol. 85, Núm. 8, pp. 1670-1683
-
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Nature Medicine, Vol. 25, Núm. 3, pp. 470-476
-
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): A harmonised study protocol for two phase i clinical trials comparing intradermal and intranodal cell administration
BMJ Open, Vol. 9, Núm. 9